Wilson-Konovalov disease in a patient after COVID-19 infection
https://doi.org/10.31146/1682-8658-ecg-199-3-161-165
Abstract
We present a rare clinical case of Wilson-C onovalov disease in a patient after a new coronavirus infection. The development of her neurological symptoms, which allowed to specify the etiology of the already existing liver damage, may have been provoked by the COVID-19 infection, in which the central nervous system is frequently involved in the pathological process. Wilson-C onovalov disease was suspected due to the presence of neurological manifestations and signs of liver cirrhosis. Subsequently, the diagnosis was confi rmed genetically, copper metabolism disorders were identifi ed and pathogenetic therapy was prescribed to eliminate excess copper from the body.
About the Authors
A. V. AparkinaRussian Federation
Alena V. Aparkina -Department of Hospital Therapy of medical faculty, Associate professor, Ph.D in Medicine.
Saratov
E. I. Kashkina
Russian Federation
Elena I. Kashkina -Department of Hospital Therapy of medical faculty, Professor, MD.
Saratov
A. A. Markova
Russian Federation
Anna A. Markova -Department of Hospital Therapy of medical faculty, Assistant, Ph.D in Medicine.
Saratov
K. D. Dorogoikina
Russian Federation
Ksenia D. Dorogoikina -Department of Hospital Therapy of medical faculty, Assistant.
Saratov
R. V. Lyakisheva
Russian Federation
Rimma V. Lyakisheva -head of Department of gastroenterology; Ph.D in Medicine.
Saratov
References
1. Lopatkina T. N. Wilson’s disease. In: Gastroenterology Manual. Moscow. 2010, pp. 579–581. (In Russ.)
2. Gomes A., Dedoussis G. V. Geographic distribution of ATP7B mutations in Wilson disease. Ann. Hum. Biol. 2016;43:1–8. doi: 10.3109/03014460.2015.1051492
3. Maevskaya M. V., Vedernikova A. V., Ivashkin V. T., et al. Wilson’s disease (clinical case presentation). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002; (5): 20–22. (In Russ.)
4. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson’s Disease. J. Hepatol. 2012; 56: 671–685. doi: 10.1016/j.jhep.2011.11.007
5. Ferenci P., Roberts E. A. Defi ning Wilson disease phenotypes: from the patient to the bench and back again. Gastroenterology. 2012;142(4):692–696. doi: 10.1053/j.gastro.2012.02.035
6. Federal clinical guidelines for the diagnosis and treatment of Wilson–Konovalov disease (hepatolenticular degeneration). Moscow. 2015. 61 P. (In Russ.)
7. Mason A., Sallie R., Perillo P., et al. Prevalence of herpes-viridae and hepatitis E virus DNA in the liver of patients with non-A , non-B fulminant hepatic failure. Hepatology. 1996; 24 (6): 1361–1365. doi: 10.1002/hep.510240608.
8. Harma M., Hockerstedt K., Lautenschlager I. Human herpes-v irus VI and acute liver failure. Transplantation. 2003; 76 (3): 536–539.
9. Lee I. C., Huo T. I., Huang Y. H. Gastrointestinal and liver manifestations in patients with COVID-19. J. Chin. Med. Assoc. 2020;83:521–523. doi: 10.1097/JCMA.0000000000000319
10. Mao L., Jin H., Wang M., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1–9. doi: 10.1001/jamaneurol.2020.1127
11. Tsimmerman Ya. S. Wilson’s disease – hepatocerebral dystrophy. Klin. med. 2017; 95(4): 310–315. (In Russ.) doi:10.18821/0023–2149–2017-95–4–310–315
12. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020; 395(10223):497-506. doi:10.1016/S0140–6736(20)30183–5
Review
For citations:
Aparkina A.V., Kashkina E.I., Markova A.A., Dorogoikina K.D., Lyakisheva R.V. Wilson-Konovalov disease in a patient after COVID-19 infection. Experimental and Clinical Gastroenterology. 2022;(3):161-165. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-199-3-161-165